Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin Therapy
Patent No. EP4338805 (titled "Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin Therapy") was filed by Amarin Pharmaceuticals Ireland on Jun 28, 2013. The application was issued on Jun 4, 2025.
Patent Summary
A pharmaceutical composition for reducing cardiovascular risk in statin-treated patients with elevated triglycerides, comprising 4g/day of eicosapentaenoic acid ethyl ester, wherein the composition contains at least 96% EPA by weight. The composition is administered orally in a capsule form and is stable for at least 12 months at room temperature. The composition is effective in preventing major cardiovascular events, including myocardial infarction, stroke, and coronary revascularization, in patients with established cardiovascular disease or at high risk for cardiovascular disease.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4338805
- Application Number
- EP24152359A
- Filing Date
- Jun 28, 2013
- Status
- Granted And Under Opposition
- May 14, 2025
- Publication Date
- Jun 4, 2025
- External Links
- Slate, Register , Google Patents